Get the Stockscreener App
7.76
2.11%
0.16
After Hours:
7.76
Engene Therapeutics Inc stock is traded at $7.76, with a volume of 211.27K.
It is up +2.11% in the last 24 hours and up +8.38% over the past month.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
See More
Previous Close:
$7.60
Open:
$7.62
24h Volume:
211.27K
Relative Volume:
0.52
Market Cap:
$519.84M
Revenue:
-
Net Income/Loss:
$-122.44M
P/E Ratio:
-3.4428
EPS:
-2.254
Net Cash Flow:
$-103.79M
1W Performance:
+6.16%
1M Performance:
+8.38%
6M Performance:
-11.82%
1Y Performance:
+94.00%
1-Day Range:
$7.31
$7.76
1-Week Range:
$7.07
$7.76
52-Week Range:
$2.65
$12.25
Engene Therapeutics Inc Stock (ENGN) Company Profile
Name
Engene Therapeutics Inc
Sector
Industry
Phone
(514) 332-4888
Address
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Therapeutics Inc
|
7.76 | 509.12M | 0 | -122.44M | -103.79M | -2.254 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Jefferies | Buy |
| Nov-11-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-18-25 | Initiated | Piper Sandler | Overweight |
| Feb-14-25 | Downgrade | UBS | Buy → Neutral |
| Dec-23-24 | Initiated | H.C. Wainwright | Buy |
| Nov-27-24 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Apr-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Mar-28-24 | Initiated | UBS | Buy |
| Mar-08-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | Leerink Partners | Outperform |
View All
Engene Therapeutics Inc Stock (ENGN) Latest News
ENGN Options Volatility — NASDAQ:ENGN - TradingView — Track All Markets
WBB Securities initiates coverage of Engene Therapeutics (ENGN) with buy recommendation - MSN
ENGN Options Chain — NASDAQ:ENGN - TradingView — Track All Markets
Engene Therapeutics Inc. Live Share Prices and Trades. ENGNW.US Live Streaming Share Prices. - London South East
ENGN Initiates Coverage On enGene Therapeutics -- Rating Set to Buy - GuruFocus
Sentiment Watch: Is enGene Holdings Inc Equity Warrant stock a value trap2026 Major Catalysts & Weekly Stock Performance Updates - baoquankhu1.vn
Published on: 2026-04-13 18:10:23 - baoquankhu1.vn
Aug Opening: Will enGene Holdings Inc stock hit new highs in YEAR2026 Support & Resistance & Risk Managed Investment Signals - baoquankhu1.vn
Revenue Check: Is enGene Holdings Inc forming bullish engulfing patterns2026 Risk Factors & High Return Trade Guides - baoquankhu1.vn
enGene Therapeutics (FRA:S0N0) Cyclically Adjusted PS Ratio : (As of Apr. 11, 2026) - GuruFocus
Total liabilities & shareholders' equities of enGene Therapeutics Inc. – FWB:S0N0 - TradingView — Track All Markets
enGene Therapeutics Inc.: Shareholders Board Members Managers and Company Profile | CA29286X1015 - marketscreener.com
S0N0: Static price chart | enGene Therapeutics Inc. | CA29286X1015 - marketscreener.com
enGene Therapeutics Inc. Changes Name and Prepares for 2027 Commercial Launch of Detalimogene Voraplasmid for High-Risk NMIBC - Minichart
enGene Therapeutics Inc.: Revenue and Earnings Analysts Forecasts Revisions | ENGN | CA29286X1015 - marketscreener.com
ENGN: Static price chart | enGene Therapeutics Inc. | CA29286X1015 - marketscreener.com
enGene Therapeutics Inc.: Target Price Consensus and Analysts Recommendations | ENGN | CA29286X1015 - marketscreener.com
enGene Therapeutics Rebrands as Company Nears Commercialization - TipRanks
Detalimogene program drives enGene (ENGN) shift to Therapeutics focus - Stock Titan
Bull Run: What analysts say about enGene Holdings Inc Equity Warrant stockFed Meeting & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Chipmakers Recap: How does enGene Holdings Inc compare to its peers2026 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
ENGE HLDGNPV: Shareholders Board Members Managers and Company Profile | CA29286M1059 - marketscreener.com
Is enGene Holdings Inc benefiting from interest rate changes2026 Market Overview & Daily Entry Point Alerts - baoquankhu1.vn
ENGNW Stock Warrant Price and Chart — NASDAQ:ENGNW - TradingView — Track All Markets
Smart Money: Is enGene Holdings Inc Equity Warrant stock a value trapMarket Risk Report & Verified Momentum Stock Watchlist - baoquankhu1.vn
EnGene Holdings Inc. will Change its Name to enGene Therapeutics Inc - marketscreener.com
enGene Therapeutics Announces Name Change Ahead of Potential 2027 Approval - National Today
enGene Announces Name Change to enGene Therapeutics Inc. - PharmiWeb.com
enGene Rebrands as enGene Therapeutics Ahead of Potential 2027 Commercial Launch - TipRanks
enGene Holdings changes name to enGene Therapeutics - Investing.com
enGene announces name change to enGene Therapeutics - TipRanks
Engene Holdings IncTo Change Name To Engene Therapeutics Inc. Effective April 8, 2026 - TradingView — Track All Markets
Three new option listings and three option delistings on April 6th - TipRanks
Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAF), Tarsus Pharmaceuticals (TARS) and enGene Holdings (ENGN) - The Globe and Mail
enGene Holdings Inc (ENGN) Income Statement - TradingKey
Market Leaders: What analysts say about enGene Holdings Inc Equity Warrant stockDollar Strength & High Accuracy Trade Alerts - baoquankhu1.vn
ENGNW SEC FilingsForbion European Acquisition Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Tangible book value per share of enGene Holdings Inc. – NASDAQ:ENGNW - TradingView
enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Down 25.3% in March - MarketBeat
Bull Run: Why is enGene Holdings Inc Equity Warrant stock going upQuarterly Profit Summary & Daily Entry Point Alerts - baoquankhu1.vn
Setup Watch: What are the analyst revisions for enGene Holdings IncIs FACT stock a good investment in YEARInflation Watch & Community Consensus Trade Alerts - baoquankhu1.vn
Energy Moves: Is enGene Holdings Inc Equity Warrant impacted by rising ratesMarket Sentiment Review & Precise Trade Entry Recommendations - baoquankhu1.vn
enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Boston Scientific (BSX) - The Globe and Mail
UBS cuts Engene Holdings stock price target on trial costs - Investing.com UK
UBS cuts Engene Holdings stock price target on trial costs By Investing.com - Investing.com South Africa
Volume Recap: Can enGene Holdings Inc Equity Warrant lead its sector in growth2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
Bank Watch: Is enGene Holdings Inc a stock for growth or value investors2026 Short Interest & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Sell Signal: How does enGene Holdings Inc compare to its peersQuarterly Risk Review & Verified Momentum Stock Alerts - baoquankhu1.vn
Valuation Update: What analysts say about enGene Holdings Inc Equity Warrant stock2026 Snapshot & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Bank Watch: Is enGene Holdings Inc Equity Warrants ROE strong enough2026 Sector Review & Verified Momentum Stock Alerts - baoquankhu1.vn
Engene Therapeutics Inc Stock (ENGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):